Vera Therapeutics, Inc.

As of October 24, 2025, Vera Therapeutics, Inc. shows a bullish technical trend supported by weekly indicators, but caution is advised due to mixed signals from monthly indicators and underperformance compared to the S&P 500.

As of October 24, 2025, Vera Therapeutics, Inc. shows a bullish technical trend supported by weekly indicators, but caution is advised due to mixed monthly signals and underperformance compared to the S&P 500.

As of October 10, 2025, Vera Therapeutics, Inc. shows a neutral technical trend with mixed indicators, including a bullish weekly MACD but a bearish monthly MACD, and has underperformed year-to-date with a return of -27.9% compared to the S&P 500's 11.41%, suggesting a cautious approach.

As of October 10, 2025, Vera Therapeutics, Inc. shows a neutral technical trend with mixed signals, underperforming the S&P 500 year-to-date by -28.85% compared to its 11.41% gain.

As of October 10, 2025, Vera Therapeutics, Inc. shows a neutral technical trend with mixed indicators, including a bullish weekly MACD but a bearish monthly MACD, and has underperformed the S&P 500 with a year-to-date return of -28.85%.

As of August 26, 2025, Vera Therapeutics, Inc. shows a mildly bearish trend with mixed technical indicators, having outperformed the S&P 500 recently but suffering significant negative returns year-to-date and over the past year.

As of June 6, 2025, the market trend is mildly bearish, primarily indicated by daily moving averages and Bollinger Bands, despite mixed signals from weekly and monthly MACD and KST indicators.

Vera Therapeutics, Inc. is a small-cap biotechnology company focused on pharmaceuticals, currently reporting a net profit loss of $52 million and a market cap of approximately $1.35 billion. The company has no dividend yield and negative return on equity.

As of Jun 18, Vera Therapeutics, Inc. has a market capitalization of $1.35 billion, with net sales of $0.00 million and a net profit of -$175.45 million over the latest four quarters. The company reported shareholder's funds of $577.15 million and total assets of $656.47 million as of Dec 24.